EUVIMEDEUVIMED entdecken
Crossref

A Comprehensive Review of Integrated Approaches to Alzheimer’s Drug Design: Heterocyclic Scaffolds for Multi-Target Modulation

Riswana R1 Riswana R1, Dr. S M Sandhya Dr. S M Sandhya, Dr. Shaiju S Dharan

International Journal of Pharmaceutical Science Invention · 2025-05 · 14 (5) · 01-15

DOI: 10.35629/6718-14050115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Pharmaceutical Science Invention, 2025-05. Verfasst von Riswana R1 Riswana R1 und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is a chronic and advancing neurological disease involving neuronal deterioration and a critical challenge to population well-being, with cases in the United States projected to reach 13.8 million by 2050. Despite its growing prevalence, a definitive ante mortem diagnosis remains unavailable, and current treatments provide only symptomatic relief without modifying the underlying disease progression. This review highlights key therapeutic targets in AD and the most effective heterocyclic scaffolds employed in the design of anti-Alzheimer’s agents. Critical targets include amyloid-beta, tau protein, tau-associated kinases like glycogen synthase kinase-3β (GSK-3β) and cyclin-dependent kinase 5 (CDK5), heat shock proteins, oxidative stress pathways, and neuroinflammatory processes. The heterocyclic scaffolds commonly used in drug design include coumarin, pyridine, carbazole, piperidine, piperazine and pyrrolidine. The multi target direct ligand (MTDL) strategy has emerged as a promising approach by incorporating multiple pharmacological actions within a single molecule to address AD's multifaceted pathology. MTDLs have demonstrated potential in modulating amyloid and tau aggregation, reducing oxidative stress, and suppressing neuroinflammation offering new hope for disease-modifying therapies. Advances in computational drug design, structure-based optimization, and hybrid pharmacophore modeling continue to accelerate the development of these novel therapeutic agents.

Zitieren

APA

R1, R. R. R., Sandhya, D. S. M. S. D. S. M., & Dharan, D. S. S. (2025). A Comprehensive Review of Integrated Approaches to Alzheimer’s Drug Design: Heterocyclic Scaffolds for Multi-Target Modulation. International Journal of Pharmaceutical Science Invention, 14(5), 01-15. https://doi.org/10.35629/6718-14050115

Vancouver

R1 RRR, Sandhya DSMSDSM, Dharan DSS. A Comprehensive Review of Integrated Approaches to Alzheimer’s Drug Design: Heterocyclic Scaffolds for Multi-Target Modulation. International Journal of Pharmaceutical Science Invention. 2025;14(5):01-15. doi:10.35629/6718-14050115

BibTeX
@article{R2025,
  author = {R1, Riswana R1 Riswana and Sandhya, Dr. S M Sandhya Dr. S M and Dharan, Dr. Shaiju S},
  title = {A Comprehensive Review of Integrated Approaches to Alzheimer’s Drug Design: Heterocyclic Scaffolds for Multi-Target Modulation},
  journal = {International Journal of Pharmaceutical Science Invention},
  year = {2025},
  volume = {14},
  number = {5},
  pages = {01--15},
  doi = {10.35629/6718-14050115}
}
Kostenlos starten →